zomaxx: abbott's drug eluting stent programme · nir 7 cell bard xt crossflex lc wallstent...
Post on 14-Aug-2020
0 Views
Preview:
TRANSCRIPT
ZoMaxx: Abbott's Drug Eluting Stent Programme
John OrmistonGreen Lane and Mercy Hospitals
Auckland, New Zealand
ZoMaxx Drug-Eluting StentZoMaxx Drug-Eluting Stent
TriMaxxStent
Platform
TriMaxxStent
Platform
PharmaCoatPolymerCoating
PharmaCoatPolymerCoating
ABT-578ABT-578
ZoMaxx™
Drug-ElutingStent
ZoMaxx™
Drug-ElutingStent
ZoMaxx Drug-Eluting StentZoMaxx Drug-Eluting Stent
TriMaxxStent
Platform
TriMaxxStent
Platform
PharmaCoatPolymerCoating
PharmaCoatPolymerCoating
ABT-578ABT-578
ZoMaxx™
Drug-ElutingStent
ZoMaxx™
Drug-ElutingStent
TriMaxx Stent PlatformTriMaxx Stent Platform
88--10 cells/ 10 cells/ perimeterperimeter
2 connectors/ 2 connectors/ circumferencecircumference
OffOff--set crown set crown connector connector
Stent Scaffolding(Mean interstrut diameter)Stent Scaffolding
(Mean interstrut diameter)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Driver TriMaxx Express 2 Vision BX Sonic
Scaf
fold
ing
Dia
met
er (m
m)
Data on file at Abbott Vascular Devices
Driver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & JohnsonDriver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson
Triplex is a trademark of Uniform Tubing, Inc.
Currently in development at Abbott Vascular Devices, not to be distributed or reproduced without permission of Abbott Vascular Devices
Tantalum provides strength and increased Tantalum provides strength and increased radioopacityradioopacityIt allows struts to be thinner without sacrificing It allows struts to be thinner without sacrificing strength or strength or radioopacityradioopacity
Triplex stent material3 layered composite
Strut thickness 0.0029”
Tantalum layer 0.0029”
Stainless steelStainless Stainless steelsteel
Stainless steelStainless Stainless steelsteel
TantalumTantalumTantalum
Stent Material andStrut Thickness
Stent Material andStrut Thickness
0.0000
0.0010
0.0020
0.0030
0.0040
0.0050
0.0060
TriMaxx Vision Driver Liberte Express 2 BX Sonic
Triplex™Triplex™
Stainless SteelStainless Steel
Lab
eled
Thi
ckne
ss (i
nche
s)
Data on file at Abbott Vascular Devices
Driver is a trademark of Medtronic; Express2 & Liberté are trademarks of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson; Triplex is a trademark of Uniform Tubing, Inc.Driver is a trademark of Medtronic; Express2 & Liberté are trademarks of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson; Triplex is a trademark of Uniform Tubing, Inc.
Cobalt ChromeCobalt Chrome
0
50
100
150
200
250
300
Strut Thickness (inches)
TantalumCobalt ChromeCobalt AlloyStainless SteelTriplex™
TantalumCobalt ChromeCobalt AlloyStainless SteelTriplex™
0.001” 0.002” 0.003” 0.004” 0.005”
MultiLink
Wiktor
Rad
iopa
city
Vision
PentaZeta
Driver Express2
Bx SonicTriMaxx
RadiopacityStrut thickness is less without sacrifice of radio-opacity
RadiopacityStrut thickness is less without sacrifice of radio-opacity
Data on file at Abbott Vascular Devices
Driver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson; Triplex is a trademark of Uniform Tubing, Inc.Driver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson; Triplex is a trademark of Uniform Tubing, Inc.
Liberté
Calibrated travelling microscope
3 points along 3 examples of each stent/delivery system
Independent Measurement of Stent/Delivery System Profile
(Diameter)
OrmistonOrmiston CCVI 2000Ormiston CCVI 2000
Ormiston
Stent Delivery System Crossing Profile
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
Tsunami
Liberte
Trimaxx
Driver
Antares
DISA
S-Flex
Duraflex
Sonic
Zeta
Bx
Velocity
Jo Stent flex
Vision
Express 2
Tetra
NirR
oyal
Penta
Tristar
Duet
BiodivYsio
S670d
BeStent2
Express
S7 Nir7 C
ell
Bard XT
Crossflex
LC
Wallstent
Wiktor I
Ave G
FX
Multilink
Dia
met
er (m
m)
FStiffness was measured using a 3 point
bend test
rr
Ormiston Cathet CardiovInterv 2000
(Instron)
Forc
e
Displacement
stiff
Less stiff
1Flexibility =
stiffness
The slope of the Force/Displacement curve is Stiffness
Stiffness is the reciprocal of Flexibility
Ormiston
Ormiston
Stiffness (reciprocal of flexibility)
0
20
40
60
80
100
120
140
160W
ikto
r
Bar
d X
TTr
imax
x
Cro
ssFl
ex
Driv
er
Tsun
ami
AV
E G
FX
Mul
tilin
k
Visi
on
Libe
rte
Due
t
Exp
ress
Exp
ress
II S7
Tris
tar
Zeta
Pen
ta
Wal
lste
nt
Tetra
S670
d
Dur
afle
x
Bio
divY
sio
Jo S
tent
DIS
A S
-Fle
x
BeS
tent
2
Bx
Vel
ocity
Ant
ares
Nir
7 C
ell
Nir
Roy
al
gms
forc
e/m
m
Expanded Mounted
Stent FlexibilityStent Flexibility
Driver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & JohnsonDriver is a trademark of Medtronic; Express2 is a trademark of Boston Scientific; Vision is a trademark of Guidant; Bx Sonic is a trademark of Johnson & Johnson
In Vitro Bench TestingIn Vitro Bench Testing
10g
Bx
10g
OC
10g
Express2
10g
Vision
10g
Driver
10g
TriMaxx
Data on file at Abbott Vascular Devices
Stent radial strength is needed especially in calcified, fibrotic, or ostial lesions to:
Resist compressive forcesMaintain sizeMaintain circular shape
Ormiston
IVUS
tecoflex
Stentpp
PRESSURE CHAMBERPRESSURE CHAMBERPRESSURE CHAMBER
Water
Ormiston
70
80
90
100
110
0 0.5 1 1.5 2 2.5 3
PRESSURE (Atmos)
% C
RO
SS-S
ECTI
ON
AL A
REA
% AREA and EXTERNAL PRESSURE(IVUS on benchtop)
Stent DStent D
Stent XStent X 10%
25%
Ormiston
Radial Strength: External Pressure and Stent Cross-sectional Area Reduction
0.0
0.5
1.0
1.5
2.0
2.5
3.0
BeS
tent
Biodivysio
JoStent
Multilink
NIR
9
Crow
n
V-Flex
Be S
tent 2
Bx Velocity
Trimaxx
Crossflex
Penta
Tsunami
Vision
Driver
Liberte
S7
Express
Duet
Tetra
Duraflex
Pres
sure
(bar
)
Mean 10% Mean 25% Collapse
Ormiston
Is the Zomaxx Stent Platform suitable for Bifurcation stenting
in the DES era?
• Stents were deployed in a phantom using contemporary bifurcation techniques
• Stents were photographed externally and internally
Ormiston
““CrushCrush”” Technique with Technique with ZomaxxZomaxx
Main Main brbr
Side Side brbr
““CrushCrush”” Technique with Technique with ZomaxxZomaxx
Deploy Deploy sideside--brbrstentstent
““CrushCrush”” Technique with Technique with ZomaxxZomaxx
Deploy main Deploy main brbrstent crushing stent crushing sideside--brbr stent in stent in main main brbr
““CrushCrush”” Technique with Technique with ZomaxxZomaxx
2 layers2 layers
3 layers3 layers
““CrushCrush”” Technique with Technique with ZomaxxZomaxx
““KissingKissing”” balloon balloon postpost--dilatationdilatation
2 layers2 layers
3 layers3 layers
Kissing balloon post-dilatation releases the side-branch from “jail”after “Crush” Bifurcation Stenting
Ormiston
Before Before ““kisskiss””SideSide--brbr jailjail
After After ““kisskiss””No Side No Side brbr jailjail
“Kissing” balloon post-dilatation after “crush” fully expands the Zomaxx stent at the side-br ostium and
corrects any main br distortion
OrmistonNo obstruction to main No obstruction to main brbr No Side No Side brbr jailjail
Well expanded Well expanded at sideat side--brbrostiumostium
The “Culotte” Technique-Provisional side-br stenting in the DES era
Ormiston 04
Trimaxx Stent after “Culotte” Bifurcation followed by “kissing” balloon post-dilatation
OrmistonMain Main brbr Side Side brbr
Trimaxx Stent after “Culotte” Bifurcation followed by “kissing” balloon post-dilatation
OrmistonMain Main brbr Side Side brbr
Trimaxx Trial (BMS)
• 100 patients to receive Trimaxx (BMS)• Single-vessel, de novo coronary lesions (Type A-
B), length > 10 mm and < 15 mm; RVD 3.0-3.75 mm
• Brazil, Germany• PI: Alex Abizaid• Primary Endpoint: MACE at 30 days• Secondary Endpoints: MACE, TLR, TVR,
ABR, Late Loss at 6 months
ZoMaxx Drug-Eluting StentZoMaxx Drug-Eluting Stent
TriMaxxStent
Platform
TriMaxxStent
Platform
PharmaCoatPolymerCoating
PharmaCoatPolymerCoating
ABT-578ABT-578
ZoMaxx™
Drug-ElutingStent
ZoMaxx™
Drug-ElutingStent
Hema-PC Lauryl HPM & SMT
Polymer- PC Technology™Polymer- PC Technology™
• PC Technology™ mimics body’s own chemistry
– Hema-PC: Mimics outer membrane of red blood cell for biocompatibility
– Lauryl: Hydrophobic for stability and adhesion to the stent surface
– Hydroxypropyl Methacrylate(HPM) & TrimethoxysilylMethacrylate (SMT): Cross-linking for durability
• Following drug elution, PC coating remains bio-inert and non-inflammatory
( ) 2 3( ) 4 7
( ) 2 5( ) 5
OO
OP
O-O O
N +
OO
OO
O H
OO
SiO C H 3O C H 3
H 3 C O
PC Technology is a trademark of Biocompatibles, Inc.
Presented by N. Chronos, TCT 2004, Washington, DC
Effect of PC coating on Inflammationin Porcine Coronary arteries
Effect of PC coating on Inflammationin Porcine Coronary arteries
0.00
0.50
1.00
1.50
2.00
0 30 60 90 120 150 180
Days after implantation
Infla
mm
atio
n Sc
o Bare Triplex (n=8)
PC-coated Triplex (n=8)
0.00
0.50
1.00
1.50
2.00
0 30 60 90 120 150 180
Days after implantation
Infla
mm
atio
n Sc
o Bare Triplex (n=8)
PC-coated Triplex (n=8)
PC Technology is a trademark of Biocompatibles, Inc.
Data on file at Abbott Vascular Devices
Effect of PC coating on Neointimal Hyperplasia in Porcine Coronary
Arteries
Effect of PC coating on Neointimal Hyperplasia in Porcine Coronary
Arteries
0%
10%
20%
30%
40%
50%
0 30 60 90 120 150 180
Days after implantation
Are
a St
enos
is (%
)Bare Triplex (n=8)
PC-coated Triplex (n=8)
0%
10%
20%
30%
40%
50%
0 30 60 90 120 150 180
Days after implantation
Are
a St
enos
is (%
)Bare Triplex (n=8)
PC-coated Triplex (n=8)
PC Technology is a trademark of Biocompatibles, Inc.
Data on file at Abbott Vascular Devices
The ZoMaxx Stent - PharmaCoatThe ZoMaxx Stent - PharmaCoat
Not approved for sale in or outside the United States.
PC topcoat
PC basecoat
ABT-578
Presented by L. Schwartz, TCT 2004, Washington, DC
Comparison of in vivo Elution RatesRabbit iliac models
Comparison of in vivo Elution RatesRabbit iliac models
Presented by A. Carter, ACC 2003, presented by B. Chevalier, PCR 2004, data on file at Abbott Vascular Devices
0
20
40
60
80
100
120
0 10 20 30Time (days)
% D
rug
elut
ed
ZoMaxx™Cypher™
0
20
40
60
80
100
120
0 10 20 30Time (days)
% D
rug
elut
ed
ZoMaxx™Cypher™
0
20
40
60
80
100
120
0 10 20 30
Time (days)
% D
rug
elut
ed
0
20
40
60
80
100
120
0 10 20 30
Time (days)
% D
rug
elut
ed Endeavor™No top coat
~75% elution in 2 days100% elution in 10 days
~75% elution in 10 days100% elution in 30 days
ZoMaxx Drug-Eluting StentZoMaxx Drug-Eluting Stent
TriMaxxStent
Platform
TriMaxxStent
Platform
PharmaCoatPolymerCoating
PharmaCoatPolymerCoating
ABT-578ABT-578
ZoMaxx™
Drug-ElutingStent
ZoMaxx™
Drug-ElutingStent
O
HO OO
ON O
O
O HO
O
OO
HO42
O
HO OO
ON O
O
O HO
O
OO
NNN
N42
FKBP BindingDomain
mTOR EffectorDomain
Rapam ycin
ABT-578
Rapamycin
ABT 578
Tetrazole ring at C42
ABT 578 is different from rapamycindue to Tetrazole group on C42
MM
GG22
GG11
SS
GG00cytostatic agentsallow cells inG0 to re-enterthe cell cycle
ABT-578 is cytostatic: blocks entry into S phase as does sirolimus
CheckpointCheckpoint
DNA synthesisprepares for mitosis
mitosis
cell responds togrowth factor stimulation
Delivered locally, ABT-578 inhibits inflammation and the proliferation of SMCsABT-578 is cytostatic by halting the cell cycle in the late G1 phase
The cell cycle and action of ABT 578
Neointimal Area (mm2)
TriMaxx Taxus Cypher ZoMaxx0
1
2
3m
m2
9 18 18
* ** **
18
*p<0.05 vs. TriMaxx
**p<0.01 vs. TriMaxx
Effect of TriMaxx, ZoMaxx, Cypher, and Taxus Stents on Swine Coronary Morphometry at 28 days (mean + SEM)
Lipophilicity of Some Clinical DES AgentsLipophilicity of Some Clinical DES Agents
Determination of Partition Coefficients for ABT-578, Rapamycin, Paclitaxel, Dexamethasone, and Estradiol at 22 deg C, Abbott Laboratories Report on File, 2004
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
1
P (C
octa
nol/C
Wat
er)
ABT-578 Rapamycin
n=16 n=16
Estadiol Dexamethasone
n=9 n=10
Paclitaxel
n=10
P<0.0001ABT-578 is 2.2 times more lipophilic than rapamycin
Lipophilicity increases tissue retention of the drug
Presented by L. Schwartz, TCT 2004, Washington, DC
Rabbit Study – Preliminary resultsComparison of Drug Levels in Arterial
Tissue for ZoMaxx Stent versus Cypher Stent
Rabbit Study – Preliminary resultsComparison of Drug Levels in Arterial
Tissue for ZoMaxx Stent versus Cypher Stent
0
20
40
60
80
100
120
140
160
0 5 10 15 20 25 30
Time (days)
Dru
g in
Tis
sue
( ug
/ g )
ZoMaxx™Cypher™
Mean ± SEMn = 4
Data on file at Abbott Vascular Devices
Cypher is a trademark of Johnson & JohnsonCypher is a trademark of Johnson & Johnson
Presented by L. Schwartz, TCT 2004, Washington, DC
bc3
슬라이드 42
bc3 the ratio between abt and sirolimus uptake in the first 4 days is around 10:1, are we sure that is safe?Bernard, 2004-05-12
Zomaxx I Trial
• 400 patients to be randomized to receive either a Zomaxx stent or a Taxus stent
• Non-inferiority trial• Primary end-point is late loss 9 month angio• Single de novo lesions • > 10 mm and < 30 mm, RVD 2.5-3.5 mm• 35 sites New Zealand, Australia, Europe• PI Bernard Chevalier
161 of 400 pts enrolled as of 15.4.05
Zomaxx II Trial
• 1670 patients will be randomized to receive either a Zomaxx stent or a Taxus stent
• Non-inferiority trial• Primary end-point is TVR• Single de novo lesions• 75 sites USA and Canada
ZOMAXX I and II Core labsZOMAXX I and II Core labs
Data Center– Harvard Clinical Research Institute, Boston
QCA – Brigham and Women’s, Boston
IVUS – Stanford Interventional Cardiology, Palo Alto
ECG – Harvard Clinical Research Institute, Boston
Presented by A. Yeung, TCT 2004, Washington, DC
Summary
• Zomaxx Stent– Trimaxx stent has excellent mechanical and
physical properties– PharmaCoat polymer safe– ABT 578 – Drug release rate similar to Cypher
• Trials -Zomaxx I underway, ZomaxxII planned
Single, de novo coronary lesions (Type A-B)with length > 10 mm and < 30 mm,
and RVD 2.5-3.5 mm.Pre-dilatation required
TAXUS™ StentN=200
ZoMaxx™ StentN=200
8, 18, 23, 33 mm 8, 18, 23, 33 mm 3.0 mm3.0 mm
8, 18, 23, 28 mm 8, 18, 23, 28 mm 2.5 mm2.5 mm
8, 18, 23, 33 mm 8, 18, 23, 33 mm 3.5 mm3.5 mm
Stent Lengths Stent Lengths Stent DiametersStent Diameters
30d 6mo 9mo 12mo 2yr 3yr 4yr 5yr
ZOMAXX I TrialRandomized, Non-inferiority Trial vs Taxus
ZOMAXX I TrialRandomized, Non-inferiority Trial vs Taxus
Clinical follow-up
Radiographic follow-up QCA/IVUS
N=40034 sitesEuropeAustraliaNew Zealand
Primary endpoint: 9-mos. in-segment late loss with equivalency limit of 0.25 mm, σ=0.4 mm;> 99% power; 1-sided α=0.05
Secondary endpoints: MACE, TVF, TLR, TVR, binary restenosis, in-stent late loss, neointimal volume, neointimal volume obstruction
Medications: Clopidogrel 75 mg QD for at least 6 months, ASA 100 mg QD ≥ 12 monthsStratification: Site
Presented by A. Yeung, TCT 2004, Washington, DC
Single, de novo coronary lesions (Type A-B)with length > 10mm and < 28mm
and RVD 2.5-3.75mmPre-dilatation required
TAXUS™ StentN=835
ZoMaxx™ StentN=835
8, 13, 18, 23, 33 mm 8, 13, 18, 23, 33 mm 3.0 mm3.0 mm
8, 13, 18, 23, 28 mm 8, 13, 18, 23, 28 mm 2.5 mm2.5 mm
8, 13, 18, 23, 33 mm 8, 13, 18, 23, 33 mm 3.5 mm3.5 mm
Stent Lengths Stent Lengths Stent DiametersStent Diameters
30d 6mo 9mo 12mo 2yr 3yr 4yr 5yr
ZOMAXX II TrialRandomized, Non-inferiority Trial, Clinical Endpoint
ZOMAXX II TrialRandomized, Non-inferiority Trial, Clinical Endpoint
Clinical follow-up
Radiographic follow-up QCA/IVUS
1670 subjects~ 75 sitesUSA and Canada
Primary endpoint: Non-inferiority to TAXUS using 9-mo ischemia driven target vessel revascularization (TVR)
Secondary endpoint: In-segment late loss at 9 mo. (QCA) Additional Analyses: Binary restenosis, MACE, TLR, TVR, in-stent late loss, neointimal volume, clinical
outcomes by vessel diameter and lesion lengthsMedications: Clopidogrel 75 mg QD for 6 months, ASA 325 mg QD for at least 12 months
Presented by A. Yeung, TCT 2004, Washington, DC
TriMaxx Stent PatternTriMaxx Stent Pattern8 or 10 cells around perimeter 8 or 10 cells around perimeter 2 connectors between rings 2 connectors between rings
O.C.C.™ (Offset Crown Connector): connecting foot pulls the rings closer together and offsets the apexes of the crowns for improved scaffolding
O.C.C.™ (Offset Crown Connector): connecting foot pulls the rings closer together and offsets the apexes of the crowns for improved scaffolding
DistalDistal
Offset
top related